Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention
Highlights
- • Preoperative intravenous antiplatelet therapy may not prevent post-operative cardiac events.
- • Bridging can be associated with a risk of clinically significant bleeding complications.
- • Patient risks should be stratified before adopting a perioperative antiplatelet management strategy.
Abstract
Background
The effect of perioperative bridging therapy on risks of ischemic cardiac events and major bleeding complications in patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) remains undefined.